|
業務類別
|
Biotechnology |
|
業務概覽
|
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States. |
| 公司地址
| 68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709 |
| 電話號碼
| +1 919 636-4530 |
| 傳真號碼
| +1 919 890-0490 |
| 公司網頁
| https://www.fennecpharma.com |
| 員工數量
| 32 |
| Mr. Robert Andrade |
Chief Financial Officer and Principal Accounting Officer |
美元 463.55K |
25/04/2025 |
| Mr. Pierre S. Sayad, M.S. |
Chief Medical Officer |
美元 81.25K |
25/04/2025 |
| Mr. Jeffrey S. Hackman |
Chief Executive Officer and Director |
美元 225.00K |
25/04/2025 |
|
|
| Dr. Jodi A. Cook, PhD |
Independent Director |
25/04/2025 |
| Mr. Chris A. Rallis |
Independent Director |
25/04/2025 |
| Mr. Jeffrey S. Hackman |
Chief Executive Officer and Director |
25/04/2025 |
| Mr. Rostislav Raykov |
Director |
25/04/2025 |
| Dr. Marco M. Brughera |
Independent Director |
25/04/2025 |
| Dr. Khalid Islam, PhD |
Chairman of the Board |
25/04/2025 |
|
|
|
|
